South San Francisco, Calif. — October 2, 2025 — Leads & Copy — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has appointed David Moore, Executive Vice President, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., to its Board of Directors.
Richard A. Miller, M.D., chairman, president, and chief executive officer of Corvus, stated that Mr. Moore’s experience leading Novo’s U.S. business, including one of the most successful GLP-1 franchises that includes Ozempic, Wegovy and Rybelsus, along with his work in corporate strategy and business development, is anticipated to be an important strategic resource as they work to maximize the potential of their ITK inhibitor platform.
Mr. Moore brings 27 years of experience in strategy, commercial, market access, business development and investing from working in both large cap pharmaceutical and biotech companies and within private equity. Mr. Moore said he looks forward to working with the team as the Company continues to advance its pipeline and growth opportunities.
Mr. Moore currently serves as Executive Vice President, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., the US operating subsidiary of Novo Nordisk A/S. He has also held positions at Gurnet Point Capital, Lysovant Sciences, and Cempra Pharmaceuticals, and Johnson & Johnson.
Corvus Pharmaceuticals is focused on pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
Source: Corvus Pharmaceuticals
